HOUSTON / LONDON (IT BOLTWISE) – Promising results from the Fine One study on finerenone were presented at Kidney Week 2025 in Houston. The drug significantly reduced the albumin-to-creatinine ratio in urine, indicating potential for treating type 1 diabetes and chronic kidney disease. At the same time, Bayer has appointed a new CFO who will take up her position from 2026.
Today’s daily deals at Amazon! ˗ˋˏ$ˎˊ˗
The latest results from the Fine One study, presented at Kidney Week 2025 in Houston, show that finerenone was able to reduce urinary albumin-creatinine ratio (UACR) by 25 percent over six months. This reduction is a significant marker of reduction in cardiovascular risk and kidney damage, making finerenone a potentially important adjunct in the treatment of patients with type 1 diabetes and chronic kidney disease.
Professor Hiddo Lambers Heerspink, who led the study, emphasized the importance of these results for medical practice. Finerenone could represent a new treatment option for patients who have previously had limited options to protect their kidney function. This development is particularly relevant as chronic kidney disease is increasing worldwide and effective treatment strategies are urgently needed.
In parallel with these scientific advances, Bayer made an important personnel decision. Judith Hartmann will take on the role of CFO from June 2026. Hartmann brings extensive experience from her time at Engie and Bertelsmann and will replace current CFO Wolfgang Nickl, who is retiring. This appointment could further strengthen Bayer’s strategic direction and financial stability.
Bayer shares reacted to these announcements with a slight decline in XETRA trading. Nevertheless, analysts see finerenone’s potential as positive for the company’s long-term development. The combination of innovative medical solutions and experienced leadership could help Bayer consolidate its position in the global pharmaceutical market.
Order an Amazon credit card without an annual fee with a credit limit of 2,000 euros!
Bestseller No. 1 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 2 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 3 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 4 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 5 ᵃ⤻ᶻ “KI Gadgets”
Please send any additions and information to the editorial team by email to de-info[at]it-boltwise.de. Since we cannot rule out AI hallucinations, which rarely occur with AI-generated news and content, we ask you to contact us via email and inform us in the event of false statements or misinformation. Please don’t forget to include the article headline in the email: “Bayer: Finerenone shows potential in kidney treatment”.